139 related articles for article (PubMed ID: 31690096)
21. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
Sams L; Slagle AF; Symonds T; Antonova J; Globe D
Value Health; 2023 Dec; 26(12):1675-1680. PubMed ID: 37748736
[TBL] [Abstract][Full Text] [Related]
22. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
Symonds T; Hackford C; Abraham L
Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
[TBL] [Abstract][Full Text] [Related]
23. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
24. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
Zagrodney KAP; Sheikhan NY; Pinto A; Sheikhan T; Witek TJ
Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
[TBL] [Abstract][Full Text] [Related]
25. Violation of US regulations regarding online marketing and sale of e-cigarettes: FDA warnings and retailer responses.
Nguyen H; Dennehy CE; Tsourounis C
Tob Control; 2020 Dec; 29(e1):e4-e9. PubMed ID: 32123138
[TBL] [Abstract][Full Text] [Related]
26. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine.
Tran A; Sheikhan NY; Sheikhan T; Nowak DA; Witek TJ
J Cannabis Res; 2021 Dec; 3(1):49. PubMed ID: 34876238
[TBL] [Abstract][Full Text] [Related]
27. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
Bramstedt KA
Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
[TBL] [Abstract][Full Text] [Related]
28. Single Cigarette Sales: State Differences in FDA Advertising and Labeling Violations, 2014, United States.
Baker HM; Lee JG; Ranney LM; Goldstein AO
Nicotine Tob Res; 2016 Feb; 18(2):221-6. PubMed ID: 25744967
[TBL] [Abstract][Full Text] [Related]
29. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
Jung M; Swann RM; Anantha MS; Jamali F
Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
[TBL] [Abstract][Full Text] [Related]
30. Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".
O'Reilly EK; Blair Holbein ME; Berglund JP; Parrish AB; Roth MT; Burnett BK
Clin Invest Med; 2013 Dec; 36(6):E290-6. PubMed ID: 24309225
[TBL] [Abstract][Full Text] [Related]
31. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Stewart KA; Neumann PJ
Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
[TBL] [Abstract][Full Text] [Related]
32. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
33. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration.
Gogtay NJ; Doshi BM; Kannan S; Thatte U
Indian J Med Ethics; 2011; 8(4):211-4. PubMed ID: 22106658
[TBL] [Abstract][Full Text] [Related]
34. Food and Dietary Supplement Package Labeling-Guidance from FDA's Warning Letters and Title 21 of the Code of Federal Regulations.
Brody T
Compr Rev Food Sci Food Saf; 2016 Jan; 15(1):92-129. PubMed ID: 33371576
[TBL] [Abstract][Full Text] [Related]
35. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023.
Patel R; Vhora A; Jain D; Patel R; Khunt D; Patel R; Dyawanapelly S; Junnuthula V
Drug Discov Today; 2024 Jun; 29(6):103993. PubMed ID: 38670257
[TBL] [Abstract][Full Text] [Related]
36. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
37. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
Chahal HS; Mukherjee S; Sigelman DW; Temple R
JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
[TBL] [Abstract][Full Text] [Related]
38. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
Alder HC
Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
[TBL] [Abstract][Full Text] [Related]
39. Your business in court and at federal agencies: 2010 - 2011.
Reiss JB; Crowder D; Simons B; Pleskov I; Davis T; Nugent P
Food Drug Law J; 2012; 67(2):243-92, iii. PubMed ID: 24620420
[TBL] [Abstract][Full Text] [Related]
40. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings.
Tucker J; Fischer T; Upjohn L; Mazzera D; Kumar M
JAMA Netw Open; 2018 Oct; 1(6):e183337. PubMed ID: 30646238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
